Literature DB >> 20406942

Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.

Beth A Zamboni1, Greg Yothers, Mehee Choi, Clifton D Fuller, James J Dignam, Peter C Raich, Charles R Thomas, Michael J O'Connell, Norman Wolmark, Samuel J Wang.   

Abstract

PURPOSE: Colon cancer overall survival (OS) is usually computed from the time of diagnosis. Survival gives the initial prognosis but does not reflect how prognosis changes with changing hazard rates over time. Conditional survival (probability of surviving y additional years given they have survived x years [CS or OS|OS]) is an alternative measure that accounts for elapsed time since diagnosis, providing more relevant prognostic information. We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS]). PATIENTS AND METHODS: Using data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS|DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS).
RESULTS: For stage II, OS|DFS improved from 87% to 92% at 5 years. For stage III, OS|DFS improved from 69% to 88%. Patients younger than 50 years showed OS|DFS improvement from 79% to 95%; those older than 70 years showed no sustained increase in OS|DFS. Node-negative patients with > or = 12 nodes resected showed little change (89% to 94%); those with more than four positive nodes showed an improvement (57% to 86%). Patients with a PS of 0 or 1 demonstrated a small improvement; those with a PS of 2 did not (64% to 58%).
CONCLUSION: Prognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes. OS|DFS is a more relevant measure of prognosis for those who have already survived disease free a period of time after diagnosis.

Entities:  

Mesh:

Year:  2010        PMID: 20406942      PMCID: PMC2881729          DOI: 10.1200/JCO.2009.23.0573

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  The conditional survival statistics for survivors with primary supratentorial astrocytic tumors.

Authors:  S L Hwang; Y H Yang; A S Lieu; M C Chuang; S J Chang; Y Y Chang; H J Lin; S L Howng
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

2.  Conditional survival in gastric cancer: a SEER database analysis.

Authors:  Samuel J Wang; Rachel Emery; Clifton D Fuller; Jong-Sung Kim; Dean F Sittig; Charles R Thomas
Journal:  Gastric Cancer       Date:  2007-09-26       Impact factor: 7.370

3.  Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

Authors:  Barry C Lembersky; H Samuel Wieand; Nicholas J Petrelli; Michael J O'Connell; Linda H Colangelo; Roy E Smith; Thomas E Seay; Jeffrey K Giguere; M Ernest Marshall; Andrew D Jacobs; Lauren K Colman; Atilla Soran; Greg Yothers; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

4.  Conditional survival among patients with carcinoma of the lung.

Authors:  R M Merrill; D E Henson; M Barnes
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

5.  Conditional survival of patients with diffuse large B-cell lymphoma.

Authors:  Michael B Moller; Niels T Pedersen; Bjarne E Christensen
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

6.  Conditional Survival in Rectal Cancer: A SEER Database Analysis.

Authors:  Samuel J Wang; Clifton D Fuller; Rachel Emery; Charles R Thomas
Journal:  Gastrointest Cancer Res       Date:  2007-05

7.  Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukemia data.

Authors:  Hans C van Houwelingen; Hein Putter
Journal:  Lifetime Data Anal       Date:  2008-10-03       Impact factor: 1.588

8.  Prognosis for long-term survivors of cancer.

Authors:  M L G Janssen-Heijnen; S Houterman; V E P P Lemmens; H Brenner; E W Steyerberg; J W W Coebergh
Journal:  Ann Oncol       Date:  2007-08       Impact factor: 32.976

9.  Ethnic disparities in conditional survival of patients with non-small cell lung cancer.

Authors:  Samuel J Wang; C David Fuller; Charles R Thomas
Journal:  J Thorac Oncol       Date:  2007-03       Impact factor: 15.609

10.  Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

Authors:  Mehee Choi; Clifton D Fuller; Charles R Thomas; Samuel J Wang
Journal:  Gynecol Oncol       Date:  2008-03-07       Impact factor: 5.482

View more
  33 in total

1.  Individualized estimation of conditional survival for patients with head and neck cancer.

Authors:  Samuel J Wang; Amanda R Wissel; Celine B Ord; Jayashree Kalpathy-Cramer; C David Fuller; John M Holland; Neil D Gross
Journal:  Otolaryngol Head Neck Surg       Date:  2011-07       Impact factor: 3.497

Review 2.  Statistical Methods for Conditional Survival Analysis.

Authors:  Sin-Ho Jung; Ho Yun Lee; Shein-Chung Chow
Journal:  J Biopharm Stat       Date:  2017-11-29       Impact factor: 1.051

3.  Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

Authors:  Lauren C Harshman; Wanling Xie; Georg A Bjarnason; Jennifer J Knox; Mary MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Min-Han Tan; Sun-Young Rha; Frede Donskov; Neeraj Agarwal; Christian Kollmannsberger; Scott North; Brian I Rini; Daniel Y C Heng; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

4.  Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study.

Authors:  Dexin Jiao; Rui Zhang; Zhiqiang Gong; Fang Liu; Yue Chen; Qinrui Yu; Liping Sun; Hongyan Duan; Shendong Zhu; Fei Liu; Jian Wang; Jianhui Jia
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

5.  Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma.

Authors:  Y Zhu; Y P Hong; H L Zhang; G H Shi; W J Xiao; Z H Wang; X D Yao; S L Zhang; B Dai; D W Ye
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-29       Impact factor: 4.553

6.  An interactive tool for individualized estimation of conditional survival in rectal cancer.

Authors:  Samuel J Wang; Amanda R Wissel; Join Y Luh; C David Fuller; Jayashree Kalpathy-Cramer; Charles R Thomas
Journal:  Ann Surg Oncol       Date:  2011-01-05       Impact factor: 5.344

7.  Prognosis and conditional disease-free survival among patients with ovarian cancer.

Authors:  Michelle L Kurta; Robert P Edwards; Kirsten B Moysich; Kathleen McDonough; Marnie Bertolet; Joel L Weissfeld; Janet M Catov; Francesmary Modugno; Clareann H Bunker; Roberta B Ness; Brenda Diergaarde
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

8.  Prognosis of Young Survivors of Gastric Cancer in China and the U.S.: Determining Long-Term Outcomes Based on Conditional Survival.

Authors:  Qi-Yue Chen; Qing Zhong; Wei Wang; Shi Chen; Ping Li; Jian-Wei Xie; Jia-Bing Wang; Jian-Xian Lin; Jun Lu; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ze-Ning Huang; Ju-Li Lin; Hua-Long Zheng; Zhi-Yu Liu; Chao-Hui Zheng; Jun-Sheng Peng; Zhi-Wei Zhou; Chang-Ming Huang
Journal:  Oncologist       Date:  2018-11-23

9.  Estimates of conditional survival in gastric cancer reveal a reduction of racial disparities with long-term follow-up.

Authors:  David Luyimbazi; Rebecca A Nelson; Audrey H Choi; Lily Li; Joseph Chao; Virginia Sun; John B Hamner; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2014-11-25       Impact factor: 3.452

10.  Conditional Survival of Esophageal Cancer: An Analysis from the SEER Registry (1988-2011).

Authors:  Ellen Kim; Siran Koroukian; Charles R Thomas
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.